[{"id":"f4599b74-514d-415f-a4c1-0ad32a88ef07","acronym":"A071401","url":"https://clinicaltrials.gov/study/NCT02523014","created_at":"2021-01-18T12:11:52.655Z","updated_at":"2025-02-25T13:11:46.229Z","phase":"Phase 2","brief_title":"Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients with Progressive Meningiomas","source_id_and_acronym":"NCT02523014 - A071401","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" PIK3CA • PTEN • CDKN2A • AKT1 • CCND1 • CCNE1 • PTCH1 • CDK4 • NF2 • SMO • CDK6 • CCND2 • CCND3","pipe":" | ","alterations":" PIK3CA mutation • PTEN mutation","tags":["PIK3CA • PTEN • CDKN2A • AKT1 • CCND1 • CCNE1 • PTCH1 • CDK4 • NF2 • SMO • CDK6 • CCND2 • CCND3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • PTEN mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • Truqap (capivasertib) • Erivedge (vismodegib) • GSK2256098"],"overall_status":"Recruiting","enrollment":" Enrollment 124","initiation":"Initiation: 09/28/2015","start_date":" 09/28/2015","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2028","study_completion_date":" 01/01/2028","last_update_posted":"2025-01-15"},{"id":"002e6ccc-3a81-4cfa-b237-64f0c73db083","acronym":"INTUITT-NF2","url":"https://clinicaltrials.gov/study/NCT04374305","created_at":"2021-01-18T21:07:59.980Z","updated_at":"2025-02-25T14:51:47.217Z","phase":"Phase 2","brief_title":"Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)","source_id_and_acronym":"NCT04374305 - INTUITT-NF2","lead_sponsor":"Scott R. Plotkin, MD, PhD","biomarkers":" NF2","pipe":"","alterations":" ","tags":["NF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nerlynx (neratinib) • Alunbrig (brigatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 06/20/2020","start_date":" 06/20/2020","primary_txt":" Primary completion: 12/01/2029","primary_completion_date":" 12/01/2029","study_txt":" Completion: 12/01/2030","study_completion_date":" 12/01/2030","last_update_posted":"2024-11-18"},{"id":"243bbd2b-9fa8-4a47-8997-af40c6654b26","acronym":"SEL-TH-1601","url":"https://clinicaltrials.gov/study/NCT03095248","created_at":"2021-01-18T15:15:00.040Z","updated_at":"2025-02-25T14:57:54.989Z","phase":"Phase 2","brief_title":"Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors","source_id_and_acronym":"NCT03095248 - SEL-TH-1601","lead_sponsor":"Children's Hospital Medical Center, Cincinnati","biomarkers":" NF2","pipe":" | ","alterations":" NF2 mutation","tags":["NF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Koselugo (selumetinib)"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 05/08/2017","start_date":" 05/08/2017","primary_txt":" Primary completion: 05/21/2024","primary_completion_date":" 05/21/2024","study_txt":" Completion: 05/21/2024","study_completion_date":" 05/21/2024","last_update_posted":"2024-10-04"},{"id":"858789a0-ffc7-4b5d-93c6-6eb6690616c1","acronym":"","url":"https://clinicaltrials.gov/study/NCT06553365","created_at":"2025-02-27T08:06:57.659Z","updated_at":"2025-02-27T08:06:57.659Z","phase":"Phase 2","brief_title":"Phase II Study of FCN-159 in NF2 Nerve Sheath Tumors","source_id_and_acronym":"NCT06553365","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" NF2","pipe":"","alterations":" ","tags":["NF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Fu Mai Ning (luvometinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/15/2024","start_date":" 08/15/2024","primary_txt":" Primary completion: 07/31/2026","primary_completion_date":" 07/31/2026","study_txt":" Completion: 07/31/2026","study_completion_date":" 07/31/2026","last_update_posted":"2024-08-14"},{"id":"80d81649-784d-4aaa-986f-3c25d334fd80","acronym":"","url":"https://clinicaltrials.gov/study/NCT04665206","created_at":"2023-08-24T11:08:27.232Z","updated_at":"2024-07-02T16:35:04.273Z","phase":"Phase 1/2","brief_title":"Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors Enriched for Tumors With NF2 or mNF2 Gene Mutations","source_id_and_acronym":"NCT04665206","lead_sponsor":"Vivace Therapeutics, Inc","biomarkers":" NF2","pipe":" | ","alterations":" NF2 mutation","tags":["NF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VT3989"],"overall_status":"Recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 03/24/2021","start_date":" 03/24/2021","primary_txt":" Primary completion: 12/24/2026","primary_completion_date":" 12/24/2026","study_txt":" Completion: 06/02/2027","study_completion_date":" 06/02/2027","last_update_posted":"2024-05-13"},{"id":"f0d76f28-ae07-45db-b977-f3917bda1843","acronym":"EAY131-U","url":"https://clinicaltrials.gov/study/NCT04439331","created_at":"2023-08-24T11:08:26.432Z","updated_at":"2024-07-02T16:35:04.943Z","phase":"Phase 2","brief_title":"Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U)","source_id_and_acronym":"NCT04439331 - EAY131-U","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" NF2","pipe":" | ","alterations":" NF2 mutation","tags":["NF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Fakzynja (defactinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 08/12/2015","start_date":" 08/12/2015","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 05/31/2025","study_completion_date":" 05/31/2025","last_update_posted":"2024-05-08"},{"id":"e4bb6ebb-d0a1-45a9-8623-25eb132314cd","acronym":"POPLAR-NF2","url":"https://clinicaltrials.gov/study/NCT05130866","created_at":"2023-08-24T11:08:27.986Z","updated_at":"2024-07-02T16:35:16.781Z","phase":"Phase 2/3","brief_title":"Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas","source_id_and_acronym":"NCT05130866 - POPLAR-NF2","lead_sponsor":"Recursion Pharmaceuticals Inc.","biomarkers":" NF2","pipe":" | ","alterations":" NF2 mutation","tags":["NF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e REC-2282"],"overall_status":"Recruiting","enrollment":" Enrollment 92","initiation":"Initiation: 06/20/2022","start_date":" 06/20/2022","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2024-03-01"},{"id":"095b86fa-4f3e-4ef0-b5ca-58c5116b56f5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05521048","created_at":"2022-08-30T20:55:54.949Z","updated_at":"2024-07-02T16:35:32.651Z","phase":"Phase 1/2","brief_title":"Doxycycline in Cutaneous Schwannoma (NF2)","source_id_and_acronym":"NCT05521048","lead_sponsor":"Massachusetts Eye and Ear Infirmary","biomarkers":" NF2","pipe":" | ","alterations":" NF2 mutation","tags":["NF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF2 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 19","initiation":"Initiation: 09/19/2022","start_date":" 09/19/2022","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-10-19"},{"id":"05930b4c-873d-4e4a-9994-ebc8a0165de0","acronym":"NF110","url":"https://clinicaltrials.gov/study/NCT04283669","created_at":"2021-01-18T20:47:46.146Z","updated_at":"2024-07-02T16:35:37.504Z","phase":"Phase 2","brief_title":"Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas","source_id_and_acronym":"NCT04283669 - NF110","lead_sponsor":"University of Alabama at Birmingham","biomarkers":" NF2","pipe":" | ","alterations":" NF2 mutation","tags":["NF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 19","initiation":"Initiation: 02/18/2020","start_date":" 02/18/2020","primary_txt":" Primary completion: 08/18/2025","primary_completion_date":" 08/18/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-09-11"},{"id":"7b27da0a-d639-42fd-a136-368d479a1f3b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02831257","created_at":"2021-01-18T13:53:02.982Z","updated_at":"2025-02-25T15:07:09.140Z","phase":"Phase 2","brief_title":"AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas","source_id_and_acronym":"NCT02831257","lead_sponsor":"Massachusetts General Hospital","biomarkers":" NF2","pipe":" | ","alterations":" NF2 mutation","tags":["NF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vistusertib (AZD2014)"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 08/31/2016","start_date":" 08/31/2016","primary_txt":" Primary completion: 05/31/2019","primary_completion_date":" 05/31/2019","study_txt":" Completion: 10/01/2020","study_completion_date":" 10/01/2020","last_update_posted":"2022-06-13"},{"id":"e14eaacb-599a-4a5f-ba1e-dd6999239c97","acronym":"","url":"https://clinicaltrials.gov/study/NCT00863122","created_at":"2021-01-18T03:17:29.085Z","updated_at":"2025-02-25T13:14:45.843Z","phase":"Phase 1","brief_title":"Concentration and Activity of Lapatinib in Vestibular Schwannomas","source_id_and_acronym":"NCT00863122","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" HER-2 • NF2","pipe":" | ","alterations":" HER-2 expression","tags":["HER-2 • NF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lapatinib"],"overall_status":"Completed","enrollment":" Enrollment 26","initiation":"Initiation: 06/01/2009","start_date":" 06/01/2009","primary_txt":" Primary completion: 08/01/2014","primary_completion_date":" 08/01/2014","study_txt":" Completion: 08/01/2014","study_completion_date":" 08/01/2014","last_update_posted":"2021-01-12"},{"id":"d8c02ed9-28f2-4a56-b232-812f5635fb39","acronym":"","url":"https://clinicaltrials.gov/study/NCT02984202","created_at":"2021-02-02T07:52:20.115Z","updated_at":"2024-07-02T16:36:42.443Z","phase":"Phase 1","brief_title":"Auditory Midbrain Implant Study","source_id_and_acronym":"NCT02984202","lead_sponsor":"Hannover Medical School","biomarkers":" NF2","pipe":"","alterations":" ","tags":["NF2"],"overall_status":"Completed","enrollment":" Enrollment 5","initiation":"Initiation: 10/17/2016","start_date":" 10/17/2016","primary_txt":" Primary completion: 06/25/2020","primary_completion_date":" 06/25/2020","study_txt":" Completion: 06/25/2020","study_completion_date":" 06/25/2020","last_update_posted":"2020-08-03"},{"id":"07327fb5-4830-4a52-b36b-d89445ebaff7","acronym":"","url":"https://clinicaltrials.gov/study/NCT02589912","created_at":"2021-02-02T07:52:18.498Z","updated_at":"2024-07-02T16:36:52.832Z","phase":"","brief_title":"Compassionate Use Arm - ABI541 ABI for 10 NF2 Patients","source_id_and_acronym":"NCT02589912","lead_sponsor":"Massachusetts Eye and Ear Infirmary","biomarkers":" NF2","pipe":"","alterations":" ","tags":["NF2"],"overall_status":"No Longer Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2019-12-06"},{"id":"a3c1849d-11da-4578-b49e-890eeda03c8c","acronym":"","url":"https://clinicaltrials.gov/study/NCT03893643","created_at":"2021-02-02T07:52:22.909Z","updated_at":"2024-07-02T16:37:01.184Z","phase":"","brief_title":"Cutaneous and Mucosal Manifestations of Neurofribromatosis Type 2 in Children Under 15","source_id_and_acronym":"NCT03893643","lead_sponsor":"Centre Hospitalier Universitaire de Nice","biomarkers":" NF2","pipe":"","alterations":" ","tags":["NF2"],"overall_status":"Recruiting","enrollment":" Enrollment 1000","initiation":"Initiation: 01/01/2019","start_date":" 01/01/2019","primary_txt":" Primary completion: 12/31/2022","primary_completion_date":" 12/31/2022","study_txt":" Completion: 12/31/2022","study_completion_date":" 12/31/2022","last_update_posted":"2019-03-28"},{"id":"088b091f-0df4-4cf7-9c2b-0f890fcab1ef","acronym":"","url":"https://clinicaltrials.gov/study/NCT01207687","created_at":"2021-01-18T04:50:27.780Z","updated_at":"2024-07-02T16:37:07.472Z","phase":"Phase 2","brief_title":"Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2)","source_id_and_acronym":"NCT01207687","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" NF2","pipe":" | ","alterations":" NF2 mutation","tags":["NF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab)"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 10/01/2010","start_date":" 10/01/2010","primary_txt":" Primary completion: 02/01/2013","primary_completion_date":" 02/01/2013","study_txt":" Completion: 03/01/2014","study_completion_date":" 03/01/2014","last_update_posted":"2018-08-27"},{"id":"77e8b8e9-1e4b-4a80-bc86-537d6d319159","acronym":"","url":"https://clinicaltrials.gov/study/NCT02387177","created_at":"2021-02-02T07:52:17.129Z","updated_at":"2024-07-02T16:37:07.785Z","phase":"","brief_title":"Resiliency Training for Adolescent Neurofibromatosis Patients Via Videoconferencing With Skype","source_id_and_acronym":"NCT02387177","lead_sponsor":"Massachusetts General Hospital","biomarkers":" NF2","pipe":"","alterations":" ","tags":["NF2"],"overall_status":"Completed","enrollment":" Enrollment 51","initiation":"Initiation: 01/01/2015","start_date":" 01/01/2015","primary_txt":" Primary completion: 12/01/2017","primary_completion_date":" 12/01/2017","study_txt":" Completion: 12/01/2017","study_completion_date":" 12/01/2017","last_update_posted":"2018-08-17"},{"id":"97cb39b3-aeeb-4a62-883e-9aa3b0114e3e","acronym":"","url":"https://clinicaltrials.gov/study/NCT00859040","created_at":"2021-02-02T07:52:11.180Z","updated_at":"2025-02-25T15:49:58.207Z","phase":"Phase 2","brief_title":"Monthly SOM230C for Recurrent or Progressive Meningioma","source_id_and_acronym":"NCT00859040","lead_sponsor":"Patrick Y. Wen, MD","biomarkers":" NF2","pipe":"","alterations":" ","tags":["NF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Signifor LAR (pasireotide long acting release)"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 03/01/2009","start_date":" 03/01/2009","primary_txt":" Primary completion: 12/01/2011","primary_completion_date":" 12/01/2011","study_txt":" Completion: 01/01/2016","study_completion_date":" 01/01/2016","last_update_posted":"2017-10-27"},{"id":"96f3dff3-79de-4269-9d22-6916c8225a53","acronym":"","url":"https://clinicaltrials.gov/study/NCT02435628","created_at":"2021-02-02T07:52:17.694Z","updated_at":"2024-07-02T16:37:23.861Z","phase":"","brief_title":"Relationship Between Psychosocial Factors, Health Literacy, Quality of Life and Satisfaction With Medical Visits in Adults With NF","source_id_and_acronym":"NCT02435628","lead_sponsor":"Massachusetts General Hospital","biomarkers":" NF2","pipe":"","alterations":" ","tags":["NF2"],"overall_status":"Completed","enrollment":" Enrollment 86","initiation":"Initiation: 02/01/2015","start_date":" 02/01/2015","primary_txt":" Primary completion: 09/01/2016","primary_completion_date":" 09/01/2016","study_txt":" Completion: 09/01/2016","study_completion_date":" 09/01/2016","last_update_posted":"2017-04-04"},{"id":"4334dd75-9bdd-4d2b-ab36-0960dc268a6d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02298270","created_at":"2021-02-02T07:52:16.802Z","updated_at":"2024-07-02T16:37:31.065Z","phase":"","brief_title":"Resiliency Training for Patients With Neurofibromatosis Via Videoconferencing With Skype","source_id_and_acronym":"NCT02298270","lead_sponsor":"Massachusetts General Hospital","biomarkers":" NF2","pipe":"","alterations":" ","tags":["NF2"],"overall_status":"Completed","enrollment":" Enrollment 65","initiation":"Initiation: 03/01/2014","start_date":" 03/01/2014","primary_txt":" Primary completion: 07/01/2015","primary_completion_date":" 07/01/2015","study_txt":" Completion: 07/01/2015","study_completion_date":" 07/01/2015","last_update_posted":"2016-06-23"}]